title: Oxaliplatin immuno hybrid nanoparticles for active targeting: an approach for enhanced apoptotic activity and drug delivery to colorectal tumors.
abstract: Tumor necrosis factor related apoptosis inducing ligand (TRAIL) proved to be a promising new target for colorectal cancer treatment. Elevated expression of TRAIL protein in tumor cells distinguishes it from healthy cells, thereby delivering the drug at the specific site. Here, we formulated oxaliplatin immunohybrid nanoparticles (OIHNPs) to deliver oxaliplatin and anti-TRAIL for colorectal cancer treatment in xenograft tumor models. The polymeric chitosan layer binds to the lipid film with the mixture of phospholipids by an ultra sound method followed by conjugating with thiolated antibody using DSPE-PEG-mal3400, resulting in the formation of OIHNPs. The polymer layer helps in more encapsulation of the drug (71 ± 0.09%) with appreciable particle size (95 ± 0.01 nm), and lipid layer prevents degradation of the drug in serum by preventing nanoparticle aggregation. OIHNPs have shown a 4-fold decrease in the IC50 value compared to oxaliplatin in HT-29 cells by the MTT assay. These immuno-nanoparticles represent the successful uptake and internalization of oxaliplatin in HT-29 cells rather than in MCF-7 cells determined by triple fluorescence method. Apoptotic activity in vitro of OIHNPs was determined by the change in the mitochondria membrane potential that further elevates its anti-tumor property. Furthermore, the conjugated nanoparticles can effectively deliver the drug to the tumor sites, which can be attributed to its ability in reducing tumor mass and tumor volume in xenograft tumor models in vivo along with sustaining its release in vitro. These findings indicated that the oxaliplatin immuno-hybrid nanoparticles would be a promising nano-sized active targeted formulation for colorectal-tumor targeted therapy.
authors.affiliation: a Department of Pharmaceutics , J.S.S College of Pharmacy (Off-campus), J.S.S University , Mysore , India .
authors.forename: Shashank
authors.initials: S
authors.lastname: Tummala
authors.affiliation: a Department of Pharmaceutics , J.S.S College of Pharmacy (Off-campus), J.S.S University , Mysore , India .
authors.forename: K
authors.initials: K
authors.lastname: Gowthamarajan
authors.affiliation: b Department of Pharmacology , J.S.S College of Pharmacy (Off-campus), J.S.S University , Mysore , India , and.
authors.forename: M N
authors.initials: MN
authors.lastname: Satish Kumar
authors.affiliation: c Department of Biotechnology , J.S.S College of Pharmacy (Off-campus), J.S.S University , Mysore , India.
authors.forename: Ashish
authors.initials: A
authors.lastname: Wadhwani
mesh_terms: D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000737:chemistry / Q000188:drug therapy*; D004337:Drug Carriers; D016503:Drug Delivery Systems; D019073:HT29 Cells; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D061986:MCF-7 Cells; D053758:Nanoparticles / Q000737:chemistry*; D009944:Organoplatinum Compounds / Q000008:administration & dosage* / Q000737:chemistry; D000077150:Oxaliplatin; D011108:Polymers / Q000737:chemistry*; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000737:chemistry / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D004337:Drug Carriers; D008055:Lipids; D009944:Organoplatinum Compounds; D011108:Polymers; D053221:TNF-Related Apoptosis-Inducing Ligand; D000077150:Oxaliplatin
keywords: Colorectal cancer; TRAIL; immuno nanoparticles; oxaliplatin; specificity